ARTICLE | Product Development
Reviving CETP
Roche, Merck data raise hopes for CETP inhibition for cholesterol lowering
September 12, 2011 7:00 AM UTC
Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc.'s torcetrapib.
Roche reported Phase IIb data in late August showing its dalcetrapib increased HDL without raising blood pressure, inflammatory markers or imaging markers correlated with vascular harm. And Merck & Co. Inc. reported similar blood pressure data for its anacetrapib last year (see BioCentury, Nov. 22, 2010)...